Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2000

View Archived Issues

Butyric acid compounds may offer antigen-specific immunotherapy

Aradigm completes phase II trial with AERx delivery of dornase alfa for CF patients

Glucophage XR: once-daily type 2 diabetes drug approved by FDA

Merger of Corixa and Coulter to create comprehensive immunotherapy company

Preliminary human safety and PK/PD findings reported for Z-13752A

Potent Na+/H+ exchange inhibitor TY-12533 displays excellent cardioprotective profile in vivo

Novartis and Bristol-Myers Squibb enter alliance for IBS and autoimmune therapy

Newest TZD approved in Europe for type 2 diabetes

Development of vaccine for genital warts discontinued

Roche creates Basilea Pharmaceutica

Inflammatory disease collaboration announced by Serono and British Biotech

Dimethaid Research seeks approval for topical osteoarthritis treatment in Canada

Second IND filed in Canada for Theratechnologies' GH-releasing analogue

Esperion acquires biotechnology company; LUV program proceeds ahead of schedule

Priority review status issued for Xyrem

NIH supports HIV research at Progenics with funding

Molecumetics and Athersys to codevelop small-molecule drugs

Bimoclomol derivative with improved pharmacological profile identified at Biorex

Peptide derivatives from Aventis modulate basement membrane synthesis

U.K. researchers patent glycopeptides that enhance T-cell proliferation

Nortran's new ion channel blockers useful as antiarrhythmics

New agents for herpesvirus infections described by Bayer

GnRH antagonists as a focus of research at Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...